Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Priority to CR7650ApriorityCriticalpatent/CR7650A/en
Publication of CR7650ApublicationCriticalpatent/CR7650A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se refiere a la sal monoclorhidrato de 2,5 -diona-3-(1-metil-1H-indol-3-il)-4-[1-(piridin-2-ilmetil) piperidin-4-il]-1H indol-3-il]-1H-pirrol cristalino, a una formulacion farmaceutica que contenga dicha sal y a procedimientos de tratamiento del cancer y de inhibicion del crecimiento tumoral utilizando dicha sal.Refers to the monohydrochloride salt of 2,5-dione-3- (1-methyl-1H-indol-3-yl) -4- [1- (pyridin-2-ylmethyl) piperidin-4-yl] -1H indole -3-yl] -1H-crystalline pyrrole, to a pharmaceutical formulation containing said salt and to methods of treating cancer and inhibiting tumor growth using said salt.
Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.